Skip to Content

  • Search

View Additional Section Content

GOG-0280 – A Phase II Evaluation of the Poly (ADP-Ribose) Polymerase (PARP) -1 and -2 Inhibitor Verliparib (ABT 888) (IND 77840) (NSC 737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Who Carry a Germline BRACA1 or BRACA2 Mutation

Clinical Trial Categories

  • Ovarian Cancer
Hanjani Institute for Gynecologic Oncology at 215-885-0220


  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory


Schedule a Test
Request an Appointment


Clinical Trials Details